Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Jaguar Health, Inc. - Common Stock
(NQ:
JAGX
)
0.4816
-0.0232 (-4.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Jaguar Health, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression
March 16, 2026
Via
ACCESS Newswire
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
March 13, 2026
From
Virtual Investor Conferences
Via
GlobeNewswire
Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts
March 11, 2026
Via
ACCESS Newswire
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
March 10, 2026
Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants
March 09, 2026
Via
ACCESS Newswire
Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1
March 03, 2026
Via
ACCESS Newswire
Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend
March 02, 2026
Via
ACCESS Newswire
Jaguar Health Announces a Special One-time Stock Dividend
February 18, 2026
Via
ACCESS Newswire
Monday's after hours session: top gainers and losers
↗
February 09, 2026
Via
Chartmill
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi
January 22, 2026
Via
ACCESS Newswire
Here are the top movers in Tuesday's session.
↗
January 20, 2026
Via
Chartmill
Unusual volume stocks are being observed in Tuesday's session.
↗
January 20, 2026
Via
Chartmill
Tuesday's session: top gainers and losers
↗
January 20, 2026
Via
Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
January 20, 2026
Via
Chartmill
Wondering what's happening in today's pre-market session?
↗
January 20, 2026
Via
Chartmill
Which stocks are moving after the closing bell on Monday?
↗
January 19, 2026
Via
Chartmill
Get insights into the top gainers and losers of Friday's after-hours session.
↗
January 16, 2026
Via
Chartmill
Which stocks are experiencing notable movement on Friday?
↗
January 16, 2026
Via
Chartmill
Curious about the most active stocks on Friday?
↗
January 16, 2026
Via
Chartmill
The Surge In Jaguar Health Stock: What's Happening Now?
↗
January 16, 2026
Jaguar Health Inc (NASDAQ:JAGX) subsidiary, Napo Pharmaceuticals, has struck a new licensing deal with Woodward Specialty.
Via
Benzinga
Keep an eye on the top gainers and losers in Friday's session.
↗
January 16, 2026
Via
Chartmill
Friday's session: gap up and gap down stocks
↗
January 16, 2026
Via
Chartmill
Get insights into the top gainers and losers of Friday's pre-market session.
↗
January 16, 2026
Via
Chartmill
Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts
January 14, 2026
Via
ACCESS Newswire
Unusual volume stocks are being observed in Tuesday's session.
↗
January 13, 2026
Via
Chartmill
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million
January 12, 2026
Via
ACCESS Newswire
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication
January 06, 2026
Via
ACCESS Newswire
Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
January 02, 2026
Via
ACCESS Newswire
Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
December 15, 2025
Via
ACCESS Newswire
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
December 10, 2025
Via
ACCESS Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.